Sector not mapped · coverage Mar 7, 2024–May 8, 2025
Estimated market comparison · not an official filing fact
Available with Pro
Average post-trade price move across enriched rows. It is historical, sample-limited, does not account for exact execution prices or portfolio weights, and is not evidence that the filing activity caused a market move.
Disclosure alert preview
Based on a real public filing
Robert P. Bresnahan
$1K - $15K
This watch matched after the disclosure became public. It is not a real-time trade signal. Source checked Aug 13, 2026.
Official filingThis page summarizes public STOCK Act disclosures involving MRNA. It is useful for seeing which lawmakers reported MRNA transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
May 8, 2025
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
Congressional Trader tracks 4 public STOCK Act disclosures for MRNAacross 3 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent MRNA filing shown here was filed on May 8, 2025 by Robert P. Bresnahan as a sale. Related lawmakers include Robert P. Bresnahan, Josh Gottheimer, Julie Johnson.
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansRecent MRNA disclosures include Robert P. Bresnahan, Josh Gottheimer, Julie Johnson.
The visible sample currently shows 1 purchases and 3 sales or partial sales.
No. This page summarizes public filings for research and monitoring. It is not investment advice.
